All In Biotech

Drug Trial Radar · NCT04504916

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

A Phase 2 Study of VLS-101 in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

102

Actual

Start

Oct 7, 2020

Primary completion

Jun 12, 2023

Study completion Jun 12, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.

Conditions

  • Triple-negative Breast Cancer
  • Non-squamous Non-small-cell Lung Cancer
  • NSCLC
  • Estrogen-receptor-positive Breast Cancer
  • Progesterone-receptor-positive Breast Cancer
  • Estrogen-receptor-negative Breast Cancer
  • ER-negative Breast Cancer
  • Progesterone-receptor Negative Breast Cancer
  • PR-negative Breast Cancer
  • HER2-negative Breast Cancer
  • ER-positive Breast Cancer
  • PR-positive Breast Cancer
  • Platinum-resistant Ovarian Cancer
  • Gastric Cancer
  • Pancreatic Cancer

Interventions

  • Zilovertamab vedotinDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)Time frame: Up to ~18 months

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005)

    Hollywood, Florida

  • AdventHealth Orlando ( Site 0003)

    Orlando, Florida

  • Massachusetts General Hospital ( Site 0017)

    Boston, Massachusetts

  • John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center ( Site 0007)

    New York, New York

  • MD Anderson ( Site 0001)

    Houston, Texas

  • The University of Texas Health Science Center at San Antonio ( Site 0004)

    San Antonio, Texas

  • Swedish Medical Center ( Site 0008)

    Seattle, Washington

  • Cross Cancer Institute ( Site 0012)

    Edmonton, Alberta, Canada

  • BC Cancer Vancouver ( Site 0011)

    Vancouver, British Columbia, Canada

  • Princess Margaret Cancer Centre ( Site 0006)

    Toronto, Ontario, Canada

  • Centre intégré de cancérologie du CHUM ( Site 0016)

    Montreal, Quebec, Canada

  • Jewish General Hospital ( Site 0013)

    Montreal, Quebec, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.